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Stem cells have been extensively investigated as tumour-tropic vectors for gene delivery to solid
tumours. In this review, we discuss the potential for using stem cells as cellular vector systems in gene
therapy for malignant gliomas, with a focus on neural stem cells, and multipotent mesenchymal stro-
mal cells. Tumour cell-derived substances and factors associated with tumour-induced inﬂammation
and tumour neovascularisation can speciﬁcally attract stem cells to invasive gliomas. Injected stem
cells engineered to produce anti-tumour substances have shown strong therapeutic effects in experi-
mental glioma models. However, the potential caveats include the immunosuppressive functions of
multipotent mesenchymal stromal cells, the contribution of stem cells to the pro-tumourigenic stroma,
and the malignant transformation of implanted stem cells. In addition, it is not yet known which stem
cell types and therapeutic genes will be most effective for the treatment of glioma patients. Here, we
highlight the possibilities and problems for translating promising experimental ﬁndings in glioma
models into the clinic.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Glioblastoma (GBM) is the most common and severe form of
malignant glioma. Despite enormous efforts, the prognosis for
GBM patients is still poor. The median survival of GBM patients
is 14.6 months, and around 10% of GBM patients survive more
than 5 years, despite receiving surgery, radiotherapy, and chemo-
therapy with temozolomide (TMZ).1,2 A major portion of treat-
ment failure is due to the invasive growth of GBM. Microscopic
tumour extensions and distant tumour microsatellites grow
along white matter ﬁbre tracts and normal brain tissue blood
vessels.3 Therefore, complete surgical resection is rarely
achieved. Other GBM therapy challenges include an increased
interstitial ﬂuid pressure within the tumour, resulting in low
concentrations of systemically delivered drugs, an intrinsic and
acquired drug resistance of tumour cells, and treatment neuro-
toxicity.4 Furthermore, although GBM presents with a dysfunc-
tional and leaky blood–brain barrier (BBB), single inﬁltrative
GBM cells reside deep within the normal brain parenchyma with
an intact BBB; therefore, they are protected from many blood-
borne drugs.5 A successful GBM treatment requires severalnter for Molecular Pathology,
78, 205 02 Malmö, Sweden.
).
Y-NC-ND license.criteria to be fulﬁlled, including the targeting of invasive tumour
cells, the targeting of tumour cells characterised by different
genetic aberrations (including putative cancer stem cells), and
the selective elimination of tumour cells while sparing normal
neural cells.6
In this review, we present the concept of using genetically engi-
neered stem cells in gene therapy for brain tumours. We discuss
different stem cell types that are used for glioma gene therapy,
mechanisms by which stem cells are attracted to tumours, and
the major principles of their therapeutic functions. We also high-
light critical issues for translating the experimental ﬁndings to
the clinic.Scientiﬁc rationale for stem cell-based therapy for GBM
Gene therapy using viral vectors has been explored in several
clinical GBM treatment trials.7 Proteins aimed at inhibiting tumour
angiogenesis, enhancing anti-tumour immune responses, and cor-
recting tumour-speciﬁc genetic defects have been expressed in
GBM by using locally or systemically administered viral gene vec-
tors. Viral-mediated GBM gene therapy has shown promising re-
sults in animal models.8 However, clinical studies have had
modest success at limiting tumour growth and extending patient
survival.7 Failure has been attributed mainly to difﬁculties in
achieving the distribution of viral vectors throughout the invasive
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has been low.7
Implanting or injecting stem and progenitor cells that have
been genetically modiﬁed to produce anti-tumour substances has
several advantages over viral-vector mediated gene delivery. Ini-
tially described by Aboody et al., implanted neural stem cells
(NSCs) possess the capacity to migrate to and within intracranial
tumours in which the NSCs deliver a cytotoxic substance that
can reduce tumour growth.9 The tumour-tropic homing and migra-
tory capacity has been replicated by many groups using different
types of stem and progenitor cells, including multipotent mesen-
chymal stromal cells (MSCs)10,11, and hematopoietic progenitor
cells (HPCs)12 in animal models. For example, a single MSC implan-
tation into an invasive rat glioma results in MSC migration to the
majority of the inﬁltrative tumour extensions and a fraction of dis-
tant tumour microsatellites.13 Differentiated cells, such as ﬁbro-
blasts, do not exhibit a similar tumour tropism.9–12 In contrast to
viral vectors, stem cells are attracted primarily to tumour tissue,
whereas they show minimal tropism for normal neural cells.
Therefore, tumour-speciﬁc gene delivery is feasible, and cerebral
side effects can potentially be avoided.9,13 Numerous studies have
demonstrated the potential of stem cell vectors in the treatment of
brain tumours and many other invasive solid tumour types.14 Thus,
although each tumour type may require tailor-made cellular vehi-
cles and transgenes, the results from work with non-neural tu-
mours may contribute to the development of a successful stem
cell therapy for GBM and vice versa.Fig. 1. (A) Phase-contrast micrograph of immortalised human NSCs after being subjected
NSCs grown as free-ﬂoating spheres in cell culture medium stimulating proliferation. (
glioma (green) implanted into the immunocompromised mouse brain. (C) Phase-contras
(D) Rat MSCs (red) inﬁltrating an invasively growing rat glioma (green) in vivo. Scale bar:
and 120 lm in D. Fig. 1B is reproduced by permission of the publisher and the author.2Different types of cell vectors
Neural stem cells
NSCs can give rise to neurons, astrocytes, and oligodendrocytes.
In the adult rodent brain, NSCs are located mainly within two neu-
rogenic zones: the subependymal zone lining the lateral ventricles
and the dentate gyrus of the hippocampus.15 In vitro, NSCs are cul-
tured and expanded as ﬂoating cellular aggregates called neuro-
spheres (Fig. 1A). Initial ﬁndings demonstrated a tumour-tropic
migration of the immortalised murine NSC line C17.2, following
implantation into, or at a distance from, the experimental gliomas.9
Subsequently, immortalised murine or human NSC lines and pri-
mary NSCs have been widely used for their tumour-tropic capacity
and potential to deliver anti-tumour substances to gliomas16–23
(Fig. 1B). An advantage of immortalised NSC lines (Fig. 1A) is that
they are readily available. A well-characterised NSC line can be cul-
tured and expanded in vitro to obtain high numbers of cells ready
for transplantation within a short period. In contrast, although it is
possible to harvest autologous neural precursor cells from the
adult human brain,24 it could take too long to expand, modify,
and characterise these cells to prepare them for implantation into
GBM patients. Furthermore, grafting immortalised NSC lines into
the brain is associated with two main problems: immunogenicity
and tumourigenicity. Immunogenicity implies that the immune
systemmay attack and neutralise the grafted non-autologous cells.
This could impair NSC survival and migration to the inﬁltrativeto cell culture conditions supporting neuronal differentiation. Insert in (A) Human
B) Immunoﬂuorescent photomicrograph of human NSCs (red) inﬁltrating a human
t photomicrograph of human MSCs growing adherently on a plastic surface in vitro.
60 lm in A (250 lm in inﬂicted neurosphere photograph), 150 lm in B, 100 lm in C,
3
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lised NSCs carrying a proto-oncogene, such as v-myc, may trans-
form and develop into secondary malignancies following
implantation into the tumour tissue. It has been reported that a
fraction of the NSCs continues to proliferate after implantation or
injection to gliomas.9,23 In addition, when subjected to growth fac-
tors and the tumour microenvironment, normal neural progenitors
in the brain can be driven towards malignant masses and poten-
tially contribute to glioma progression.25,26 It will be important
to determine whether implanted and in vivo proliferating NSCs
can form tumourigenic masses after long-term growth in vivo.
One way to avoid such an occurrence would be to administer NSCs
that are genetically modiﬁed to carry a ‘‘suicide’’ gene, such as her-
pes simplex virus thymidine kinase (HSV-tk). With this approach,
it would be possible to eliminate the administered NSCs within
the tumours at any given time.
Multipotent mesenchymal stromal cells
Multipotent mesenchymal stromal cells, sometimes called mes-
enchymal stem cells, are non-hematopoietic stem cells. MSCs are
thought to be the precursors of the bone marrow stroma; at a min-
imum, they can differentiate into chondrocytes, adipocytes, and
osteoblasts.27 MSCs are usually isolated by their adherent growth
in culture (Fig. 1C), differentiation capacity, expression of surface
markers (including CD73, CD90, CD105, CD146, CD271, and
STRO-1) and lack of expression of the hematopoietic markers
CD34 and CD45.27
Intracranially implanted or injectedmouse, rat, and humanMSCs
have shown tropism for experimental gliomas in which MSCs can
deliver a therapeutic substance leading to an increased survival of
the glioma-bearing animals.10,11 However, rat MSCs lack the long-
distance migratory capacity through normal brain tissue towards
the rat gliomawhen implanted at a distance (i.e., a fewmillimetres)
from the tumour.28 In contrast, intratumoural implantation of rat
MSCs directly into rat gliomas results in an MSC migration to the
majority of invasive tumour extensions and a fraction of distant tu-
mour microsatellites13 (Fig. 1D). Importantly, the tumour-speciﬁc
distribution of intratumourally implantedMSCmakes the cells well
suited for transporting toxic substances speciﬁcally into tumours
while potentially sparing the normal brain tissue.13
MSCs are promising cell therapy candidates because it is easy to
obtain MSCs through a bone marrow puncture and, subsequently,
to culture and expand the cells in vitro. In principle, this makes it
possible to graft autologous MSCs (isolated from the patient).
Autologous MSC implantation would avoid graft rejection, but
expansion, modiﬁcation, and characterisation of the MSCs would
delay the onset of treatment compared to implantation of a readily
available, well-characterised cell line. In addition, there are a num-
ber of concerns about the use of MSCs for tumour gene therapy.
The ﬁndings from other solid tumour types have shown that MSCs
may contribute to tumour growth through their immunosuppres-
sive properties, growth factor production, and contribution to the
pro-tumourigenic stroma, as well as by the malignant progression
of the recruited MSCs, which can drive tumour growth.29–33 As part
of the tumour microenvironment, MSCs can promote experimental
ovarian cancer growth34 and increase the metastatic capacity of
breast cancer cells.35 In contrast, non-modiﬁed MSCs can reduce
tumour vascularisation and suppress tumour growth in a malig-
nant melanoma model.36 Importantly, independent groups have
reported that implanted non-modiﬁed human or rat MSCs display
no glioma-promoting effects.13,37 Other ﬁndings suggest a glioma-
suppressing effect upon implanting human adipose tissue-derived
MSCs38 or bone marrow-derived rat MSCs11 into gliomas. These
divergent results may depend on the differences in MSC sub-pop-
ulations (e.g., heterogeneity of MSCs within and between the cellcultures leading to functionally different MSCs in different experi-
ments)39,40 and MSC species differences (human MSCs may not
necessarily yield the same results as mouse and/or rat MSCs).
The conﬂicting ﬁndings of the interaction between MSCs and tu-
mour cells are further reviewed in the literature.41 The potential
risk that human MSCs can undergo transformation into malignant
cells under in vitro culture conditions is controversial and reviewed
by Prockop et al.42Alternative types of cellular vectors
Other types of stem and progenitor cells may also serve as
migratory vectors to gliomas. The hematopoietic progenitor cell
(HPC) is an easily accessible cell type with glioma tropism.12 Sys-
temically injected human peripheral blood-derived and murine
bone marrow-derived HPCs are attracted speciﬁcally to experi-
mental gliomas through transforming growth factor (TGF)-b and
stromal cell-derived factor-1a (SDF-1a)/CXC chemokine ligand
12-dependent migration and homing.12 Tumour endothelial cells
express E-selectin (CD62E), which is critical for HPC homing to gli-
omas by mediating adhesion of circulating HPCs to glioma endo-
thelium.43 Hypoxia, cerebral irradiation, and chemotherapy
(TMZ) further enhance HPC attraction to tumour cells, suggesting
that a combined treatment approach by HPCs and irradiation
and/or chemotherapy may be advantageous.44
Implanted human skin-derived stem cells can migrate to exper-
imental gliomas in which the cells reduce tumour angiogenesis and
adopt a pericytic phenotype. The effects on glioma growth and pro-
longed animal survival indicate that skin-derived cells may be an
autologous alternative for stem cell therapy of gliomas.45
Furthermore, systemically injected endothelial progenitor cells
can home to experimental gliomas and integrate into the tumour
vasculature.46,47 Therapeutic anti-glioma effects have been
achieved by injecting endothelial progenitor cells that have been
modiﬁed to produce oncolytic measles virus48 or engineered to
express cytotoxic anti-tumour genes.46
Embryonic stem cell-derived astrocytes have shown intracra-
nial migratory capacity and therapeutic efﬁcacy following implan-
tation into subcutaneously established gliomas.49 NSCs generated
from induced pluripotent stem (iPS) cells have also been used as
vectors in glioma gene therapy50; however, compared to the other
cell vectors described above, the clear advantages of using iPS cells
for glioma gene therapy have not yet been demonstrated.
Thus, different types of stem and progenitor cells have been uti-
lised for glioma gene therapy, and each cell type has advantages
and disadvantages. There are at least three critical requirements
that cell carriers should meet: (1) neoplasm-speciﬁc extensive
migration within the glioma and to inﬁltrative GBM cells; (2)
stable production and delivery of an oncolytic substance; and (3)
implanted cells should not cause any substantial harm to the
surrounding brain parenchyma. However, studies comparing
migratory potential, proliferative capacity, cell survival, and deliv-
ery efﬁcacy of different cellular vectors implanted into intracranial
gliomas are lacking and highly warranted.Mechanisms of migration
Neural stem cells and MSCs have been delivered to orthotopic
glioma in preclinical studies by various routes of administration.
The different ways to administer therapeutic stem cells to gliomas
include direct implantation into tumours, intracerebral injection at
a site located at a distance from the tumour, injection in the
contralateral hemisphere, intracerebroventricular deposition,
intravenous injection and intra-arterial injection.9,10,19,21,51,52
Although intratumoural MSC grafting can yield effective and
Fig. 2. Schematic illustration of the major mechanisms contributing to tumour-
selective tropism of grafted stem cells in glioblastoma.
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not clear which is the preferred route of administration.
A schematic overview of tumour components regulating stem
cell migration is given in Fig. 2. In the following section we present
a detailed description of the mechanisms underlying stem cell tro-
pism for tumours.
Inﬂammatory-derived factors can attract NSCs and MSCs to
glioma. The peritumoural oedema zone in glioma is characterised
by a high number of activated astrocytic and microglial cells and
constitutes an inﬂammatory tumour microenvironment.53 Several
factors, notably interleukin (IL)-8,54 monocyte chemotactic protein
(MCP)-1,55 SDF-1a,56 are present within glioma or in the peritumo-
ural reactive region and have been implicated in MSC migration to
tumours. For instance, tumour necrosis factor-a can enhance the
expression of CXC chemokine receptor (CXCR) 4 on MSCs, which
results in increased MSC migration towards stroma-derived SDF-
1a.57 MCP-1 expression in gliomas can mediate glioma-tropic
migration of NSCs through the CC chemokine receptor 2.58 Thera-
peutic irradiation produces an inﬂammatory response, and MSC
tropism to the glioma is increased following brain irradiation.59,60
The irradiation-enhanced MSC tumour tropism is mediated in part
by an increased IL-8 production from irradiated gliomas and
CXCR1 upregulation on migratory MSCs.59 Further information
describing MSC migration to the inﬂammatory components of
tumours is detailed by Spaeth et al.61
In addition to inﬂammation, tumour angiogenesis and angio-
genic signalling molecules inﬂuence MSC tropism to neoplasms.
Findings from in vitro assays suggest that platelet-derived growth
factor (PDGF)-BB, PDGF-D, vascular endothelial growth factor
(VEGF)-A, TGF-b1, and neurotrophin-3, all of which are involved
in tumour angiogenesis, mediate MSC recruitment to glio-
mas.10,62,63 Intratumourally grafted MSCs exhibit a marked tropism
to tumour vasculature following intratumoural grafting, integrate
into tumour vessel walls, and display a pericyte-like phenotype.13
Tumour angiogenic signalling factors may also regulateMSCmigra-
tion intratumourally in vivo.13 Glioma angiogenesis inhibition, by
the anti-angiogenic drug sunitinib, substantially decreases the
migration of grafted MSCs to tumours, indicating that tumour angi-
ogenesis is critical for intratumoural MSC migration.13 Angiogenic
signalling has also been demonstrated to be important for NSC
tracking of glioma cells.64 The dependence on ongoing angiogenic
signalling may confer a powerful glioma speciﬁcity to grafted,migratory stem cells because there is no active angiogenesis in the
surrounding normal brain. Hypoxia upregulates CXCR4, urokinase
plasminogen activator (uPA) receptor, and VEGF receptor 2 onNSCs,
which enhances their migration towards gliomas.65 These ﬁndings,
in combinationwith the observed localisation of injectedNSCs close
to hypoxic areas within experimental gliomas, suggest that hypoxia
is a critical factor for NSC tropism for gliomas.65
The migrating MSCs interact with and remodel the extracellular
matrix (ECM) during migration. Matrix metalloproteinase (MMP)-
1, a matrix-degrading enzyme, is upregulated speciﬁcally in MSCs,
displaying a high propensity for glioma-directed migration.
Conversely, overexpression of MMP-1 on relatively immobile sub-
populations of MSCs increase their migration towards gliomas.66
The composition of the glioma-derived ECM also inﬂuences NSC
migration towards inﬁltrating glioma cells.67
Interestingly, molecules involved in chemotaxis during normal
development are upregulated in malignant brain tumours and aug-
ment NSC and MSC tropism. Human NSCs are attracted to glioma
cell-derived factors (hepatocyte growth factor, epidermal growth
factor (EGF) and VEGF, uPA, and uPA receptor). It has been sug-
gested that NSCs and migratory glioma cells use the same or sim-
ilar pathways to enable their motility.68
Most mechanistic ﬁndings underlying NSC and MSC glioma tro-
pism have been derived from in vitro experiments. These results
have to be interpreted with caution because the in vivo tumour
microenvironment is much more complex compared to the artiﬁ-
cial in vitro microenvironment. Nevertheless, in vitro mechanistic
knowledge responsible for NSC and MSC tumour tropism has been
exploited to increase the efﬁcacy of brain tumour homing for ther-
apeutic purposes. EGF receptor overexpression on MSCs increases
their inﬁltration into EGF-expressing gliomas.69 Similarly, CXCR3
overexpressing HiB5 neural progenitor cells (NPCs) exhibit en-
hanced in vivo migration towards rat gliomas compared to non-
transduced HiB5 cells.70Anti-tumour substance delivery
Pro-inﬂammatory cytokines
A variety of cytokines have been delivered by NSCs or MSCs to
gliomas and have demonstrated therapeutic efﬁcacy alone or in
combination with other treatment modalities.10,17,71,72 Early work
demonstrated the therapeutic effects of implanting IL-4-producing
NSCs on murine glioma growth.16 Notably, the effects of NSC-pro-
duced IL-4 were more powerful than virus-mediated transfer of IL-
4.16 Interleukin-mediated effects are related to a pro-inﬂammatory
reaction, including an increased inﬁltration of anti-tumour im-
mune cells (e.g., CD4+ and CD8+ cytotoxic T-cells and natural killer
cells) into tumours.71,72 The anti-tumour immune response can be
further enhanced by combining the intratumoural implantation of
cytokine-producing MSCs with systemic immunotherapy.72Tumour necrosis factor-related apoptosis-inducing ligand
Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) activates the pro-apoptotic death receptors (DRs) 4 and
5, which induce caspase-8-dependent apoptosis.73 TRAIL can selec-
tively target tumour cells while sparing most non-malignant
cells.74 TRAIL-producing NSC implantation into human gliomas in
mice leads to increased tumour apoptosis and decreased tumour
growth. However, the normal neural cells do not undergo apopto-
sis.75 Several studies have shown therapeutic and tumour-speciﬁc
effects by intracranially implanting or intravenously injecting
TRAIL-producing MSCs,37,76–78 NPCs,79 or ESC-derived astrocytes49
into experimental gliomas.
Table 1
Selected preclinical stem cell-based glioma therapy studies.
Therapeutic modiﬁcation of stem cells Substance Cell type Route of administration Ref.
Pro-inﬂammatory cytokines IL-4 NPC co-injection/i.t. 16
IL-7a MSC i.t. 72
IL-12 NSC i.t./i.c. 17
IL-23 BM-NSLC i.t. 71
IFN-b MSC i.t. 10
Tumour apoptosis-inducing substances TRAIL NSC i.t. 75
S-TRAILb NSC i.c. 79
S-TRAIL MSC i.c. 77
S-TRAIL MSC co-injection/i.t. 37
Pro-drug converting enzymes CDc NSC co-injection 9
HSV-tkd NSC In vitro study 85
HSV-tkd BM-TIC i.t. 83
Oncolytic viruses HSV-1 NSC i.t. 91
CRAd MSC i.c. 93
CRAd MSC i.a. 94
Antibodies scFv anti-EGFRvIII MSC co-injection/i.t. 96
Abbreviations: BM-NSLC, bone marrow-derived neural stem-like cell; CD, cytosine deaminase; CRAd, conditionally replicating adenovirus; EGFR, epidermal growth factor
receptor; HSV-1, herpes simplex virus type 1; HSV-tk, herpes simplex virus type 1 thymidine kinase; i.a., intra-arterial; i.c., intracerebral (at a distance from the tumour); i.t.,
intratumoural; IL, interleukin; MSC, multipotent mesenchymal stromal cell; NPC, neural progenitor cell; NSC, neural stem cell; scFv, single-chain antibody fragment; TRAIL,
tumour necrosis factor-related apoptosis-inducing ligand.
a Combined with peripheral immunotherapy.
b Combined with PI-103.
c Combined with 5-ﬂuorocytosine.
d Combined with ganciclovir.
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PEX is a human MMP-2 fragment that exerts anti-tumour ef-
fects by inhibiting glioma angiogenesis and tumour cell prolifera-
tion.80 Intracranial implantation of human immortalised NSCs
that are modiﬁed to produce PEX leads to decreased tumour vascu-
larisation and tumour cell proliferation, resulting in an inhibited
glioma growth.18Pro-drug converting enzymes (‘‘suicide’’ gene therapy)
Enzymes capable of converting inactive pro-drugs into toxic
substances have been widely used in clinical glioma gene therapy.
The intratumoural transfer of herpes simplex virus type 1 thymi-
dine kinase (HSV-tk) in combination with the pro-drug ganciclovir
(GCV) is the most extensively studied system. HSV-tk phosphory-
lates the guanosine analogue GCV, which is then incorporated into
the DNA strand, leading to disturbed DNA synthesis and cell death.
The activated GCV is toxic to the HSV-tk-producing cells and the
cells in their vicinity. This is due to a bystander effect, exerted by
gap junctions between the cells through which the phosphorylated
pro-drug is transported.81 In clinical trials, HSV-tk has been trans-
ferred to tumours mainly using viral gene vectors. A phase III mul-
ticenter randomized clinical trial including 248 GBM patients
showed no signiﬁcant difference in survival between the HSV-tk
gene therapy group and control group.82 HSV-tk clinical gene ther-
apy studies are reviewed by Pulkkanen et al.7 It was shown that the
therapeutic effects were poor due to a low transduction efﬁciency
of tumour cells in vivo and an ineffective vector distribution within
the tumours.7 Consequently, migratory stem cell vectors have been
introduced in preclinical studies to achieve a better intratumoural
distribution of the pro-drug converting enzyme. Indeed, HSV-tk
transfer using bone marrow-derived progenitor cells,83 NSCs,84,85
and MSCs,52 can lead to therapeutic effects through bystander-
mediated glioma cell killing.83,85,86
Another well-investigated pro-drug activating enzyme is cyto-
sine deaminase (CD), which converts 5-ﬂuorocytosine (5-FC) to
its toxic form, 5-ﬂuorouracil, causing cell death.87 CD-expressing
NSCs have been used to treat intracranial rat gliomas9 or humanmedulloblastomas in immunocompromised mice.88 In 2010, a clin-
ical pilot trial using immortalised NSCs engineered to produce CD
in combination with oral 5-FC was initiated for patients undergo-
ing surgery for recurrent high-grade gliomas. The aim of the study
is to clarify the safety and feasibility of intracerebral NSC implan-
tation and systemic 5-FC administration in glioma patients (Clini-
calTrials.gov; Identiﬁer: NCT01172964). Obviously, two critical
issues for achieving therapeutic effects are the distribution of the
pro-drug converting enzyme (i.e., administered stem cells) to the
invasive glioma and the magnitude of the bystander effect in vivo.
Oncolytic viruses
In oncolytic virotherapy, viruses with the capacity to infect tu-
mour cells are delivered systemically or locally to tumours. The
viruses replicate within and lyse the tumour cells, whereby they
are released for subsequent uptake by the neighbouring tumour
cells. Although oncolytic virotherapy has delivered promising pre-
clinical results, there are several obstacles for a successful clinical
translation. First, viral particle delivery throughout the tumour tis-
sue and to invasive tumour cells has been difﬁcult. Second, the host
immune system can attack and neutralise the viral particles before
they can exert any effect.89 It is possible to deliver viral particles to
distant parts of the tumour using tumour-tropic migratory cells as
oncolytic virus carriers. Furthermore, the viral particles within
cells may be protected from the immune system.90 NSCs, MSCs,
and adipose-derived stem cells have been used for delivering onco-
lytic viruses (e.g., a conditionally replicating adenovirus) to exper-
imental gliomas. These results suggest that stem cell-mediated
oncolytic virus delivery is superior to viral delivery alone for the
survival of glioma-bearing animals.22,91–94
Antibodies
The administration of engineered stem cells may be an effective
way to sustain local anti-tumour antibody delivery. Furthermore,
stem-cell-based delivery of antibodies has the potential to reduce
the toxic side-effects caused by intravenous antibody administra-
tion.95 Co-injection of human glioma xenografts and human MSCs
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(scFv) against the EGF receptor variant III results in reduced tu-
mour vascularisation and increased survival of glioma-bearing
mice.96
Table 1 summarises selected preclinical stem cell-based glioma
therapy studies.Towards an effective stem cell-based therapy for malignant
glioma
The tumour-tropic migration of human, rat, and mouse NSCs
and MSCs is associated with general GBM features (e.g., neovascu-
larisation, inﬂammation, and growth factor production) and,
importantly, is not animal model-speciﬁc. Therefore, it is conceiv-
able that implanted human stem and precursor cells will migrate
within vascularised tumours of patients. A prospect for stem cell-
based therapy for treating glioma patients includes implanting
genetically modiﬁed stem cells into the remaining tumour after a
surgical resection. One alternative could be to inject stem cells at
multiple sites to target as many distant tumour satellites as
possible. Subsequent stem cell implantations could be performed
at later times using image-guided stereotaxic techniques. Irradia-
tion can enhance tumour-tropic stem cell migration; therefore, a
combined treatment with stem cells and radiotherapy may be
effective.59,60
However, even though the basic ﬁndings support the use of
stem cell vectors in tumour therapy, numerous hurdles should be
overcome. Here, we outline the future advancements in four areas,
which will be important for clinical cell therapy development for
glioma treatment.
Stem cell biology
The divergent results obtained from studying the interaction
between stem cells, in particular MSCs, and tumour cells (dis-
cussed previously and reviewed by Klopp et al.41) highlights the
need for further studies on stem cell biology and the interplay be-
tween stem cells and gliomas in vivo. It is crucial to characterise
the different MSC populations and to elucidate how they function
with GBM tumour and stromal cells. Similarly, a deeper under-
standing of the interaction between NSCs and GBM tissue can lead
to a safer and more effective stem cell-based therapy against
gliomas.
Animal models
Preclinical results have been obtained from the use of glioma
animal models that have been established only a few days prior
to the initiation of treatment. The results derived from such studies
can be valuable; currently, however, the experimental glioma fea-
tures do not necessarily resemble the complex GBM characteristics
in a patient. To show the clinical potential, experimental studies
need to be designed in a ‘‘clinical time frame’’ manner. In particu-
lar, it is important to develop effective experimental stem cell-
based therapies against glioma animal models that are highly inﬁl-
trative, vascularised and cellularly and genetically heterogeneous
at the onset of treatment.
Choice of cell type and transgene
It is difﬁcult to compare the results of many of the preclinical
studies because there are important differences in the experimen-
tal settings. Thus, it would be valuable to systematically compare
the migratory capacity and the long-term fate (i.e., proliferation
and survival) of the different tumour-tropic cell types in gliomamodels. Similarly, the choice of stem cell-delivered therapeutic
transgenes should be evaluated in a more systematic and compar-
ative way. The results from such studies would provide valuable
information when planning clinical trials.
Imaging
Non-invasive imaging will be important for following the
migration and survival of implanted/injected stem cells into glio-
mas. Bioluminescence imaging, magnetic resonance imaging and
positron emission tomography have been used to detect adminis-
tered stem cells in glioma animal models.21,23,83 The different
imaging modalities will provide information concerning the long-
term fate of the implanted stem cells. Further technological
improvements can provide a higher spatial resolution with the po-
tential to trace stem cells at a single-cell level within gliomas.Conclusions
Stem cell vectors may, by their capacity to target inﬁltrative tu-
mour cells, provide a powerful treatment modality for GBM. How-
ever, many issues, including the choice of cell vector, choice of
therapeutic transgene, the optimal route of administration and
biosafety, need to be addressed. In light of the previous difﬁculties
in translating experimental glioma therapy into successful clinical
therapy, researchers should make a systematic and concerted ef-
fort to further examine the problems and the possibilities associ-
ated with stem cell vectors in order to clarify their clinical
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